SAN FRANCISCO--(BUSINESS WIRE)--A poster describing the results of the final Phase 3 clinical trial for crofelemer, a drug being developed for the indication of chronic diarrhea in people living with HIV/AIDS on anti-retro viral therapy (CRO-HIV), was presented in Seattle this afternoon. The presentation took place as part of a session titled, “ADVENT Trial: Crofelemer for the Treatment of Secretory Diarrhea in HIV+ Individuals” during the Conference on Retroviruses and Opportunistic Infections (CROI). Crofelemer is a product of San Francisco-based Napo Pharmaceuticals, Inc.
